Kane Biotech Unveils Clinical Data on revyve® at SAWC Fall Conference

Kane Biotech Inc. announced that Interim Chief Executive Officer, Dr. Robert Huizinga, will present clinical data on its revyve® products at the Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas, Nevada, from September 3-6, 2025. The data focuses on the effectiveness of revyve® in treating complex wounds that have persisted for over two years.

The SAWC is renowned for bringing together a multidisciplinary community of wound care professionals, including physicians, nurses, and researchers. Participants share evidence-based practices and clinical innovations aimed at enhancing wound management and patient outcomes. At this year’s conference, two significant presentations will highlight the efficacy of revyve®.

Case Study Highlights

The first presentation will detail the clinical use of a novel thermo-reversible antimicrobial wound gel designed to fill deep cavity wounds while reducing pain and exudate levels. In one instance, revyve® was applied to a two-year-old non-healing Stage 4 sacral ulcer in an elderly patient, initially presenting with a pain score of 10/10. Previous treatments had included daily dressing changes with silver-based antimicrobial agents. Following the application of revyve®, pain scores dropped to 0, and wound size decreased significantly over three weeks. Furthermore, a reduction in Klebsiella pneumonia cultures was also observed throughout the treatment period, which lasted two months.

The second case study will focus on vibrational debridement combined with revyve® for a non-healing venous leg ulcer (VLU). An elderly female patient, suffering from a full-thickness wound characterized by slough, eschar, and necrotic tissue, reported initial pain levels of 5/10. After three weeks of treatment with revyve®, her pain levels decreased to 0, alongside a notable 60% reduction in wound size over eight weeks. The treatment also resulted in a decrease in discharge, indicating significant progress in healing.

FDA Clearance and Future Plans

Kane Biotech’s revyve® Antimicrobial Wound Gel and Wound Gel Spray have received clearance from the U.S. Food and Drug Administration (FDA) under the 510(k) process, ensuring their safety and efficacy for clinical use. At the SAWC conference, the company will showcase these products and will also engage with potential U.S. distributors to expand its market reach.

Kane Biotech focuses on developing innovative wound care solutions that target biofilms, a significant contributor to antibiotic resistance in wounds, which can lead to severe clinical outcomes. The company’s revyve® products are designed to address both biofilms and wound bacteria effectively. In addition to FDA clearance, revyve® Antimicrobial Wound Gel is also approved by Health Canada.

For more information about Kane Biotech and its advancements in wound care, visit their official website or follow them on social media. The company encourages those interested to join its distribution list for the latest updates on its products and research.

As Kane Biotech continues to innovate, its presentations at the SAWC Fall Conference could signal a transformative step in wound care management, particularly for patients with chronic and complex wounds.